{"title":"Upsher-Smith将收购CNS合作伙伴Proximagen","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I6.1761","DOIUrl":null,"url":null,"abstract":"Upsher-Smith Laboratories has agreed to acquire the 84% of its CNS partner Proximagen that it does not already own in a deal worth up to £356.8 M (US$554 M). For each Proximagen share, Upsher-Smith will pay £3.20, which represents a 16% premium over Proximagen’s closing price prior to the announcement of the transaction. The deal also includes contingent value rights relating to the success of two Proximagen compounds: the Phase I vascular adhesion protein-1 (VAP1) inhibitor for rheumatoid arthritis and PRX00933, which has completed Phase II development for the treatment of obesity","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"31 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Upsher-Smith to Take Over CNS Partner Proximagen\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I6.1761\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Upsher-Smith Laboratories has agreed to acquire the 84% of its CNS partner Proximagen that it does not already own in a deal worth up to £356.8 M (US$554 M). For each Proximagen share, Upsher-Smith will pay £3.20, which represents a 16% premium over Proximagen’s closing price prior to the announcement of the transaction. The deal also includes contingent value rights relating to the success of two Proximagen compounds: the Phase I vascular adhesion protein-1 (VAP1) inhibitor for rheumatoid arthritis and PRX00933, which has completed Phase II development for the treatment of obesity\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"31 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-06-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I6.1761\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I6.1761","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
upher - smith Laboratories已同意以高达3.568亿英镑(合5.54亿美元)的价格收购其CNS合作伙伴Proximagen尚未拥有的84%股份。对于Proximagen的每股股份，upher - smith将支付3.20英镑，这比Proximagen在交易宣布前的收盘价溢价16%。该交易还包括与Proximagen两种化合物成功相关的或有价值权:用于类风湿性关节炎的I期血管粘附蛋白-1 (VAP1)抑制剂和PRX00933, PRX00933已完成治疗肥胖的II期开发
Upsher-Smith Laboratories has agreed to acquire the 84% of its CNS partner Proximagen that it does not already own in a deal worth up to £356.8 M (US$554 M). For each Proximagen share, Upsher-Smith will pay £3.20, which represents a 16% premium over Proximagen’s closing price prior to the announcement of the transaction. The deal also includes contingent value rights relating to the success of two Proximagen compounds: the Phase I vascular adhesion protein-1 (VAP1) inhibitor for rheumatoid arthritis and PRX00933, which has completed Phase II development for the treatment of obesity
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
